Sun Pharma Advanced Research Company (SPARC) jumped 6.87% to Rs 197.50, extending gains for the second day.
The stock has added 8.57% in two sessions, from its recent closing low of Rs 181.45 recorded on 6 May 2021.
In the past one month, the stock has zoomed 17.53% while the benchmark Sensex shed 0.08% in the same period.
On the technical front, the stock's RSI (relative strength index) stood at 69.860. The RSI oscillates between zero and 100. Traditionally, the RSI is considered overbought when above 70 and oversold when below 30.
The stock was trading above its 50-day, 100-day and 200-day daily simple moving average (SMA) placed at 165.45, 176.10 and 175.73, respectively.
In a regulatory filing made on Sunday (9 May 2021), SPARC said that its board will meet on Wednesday, 12 May 2021, to consider and evaluate proposals for raising of funds in one or more tranches by way of issue of equity shares or securities/warrants convertible into equity shares of the company, through permissible modes including by way of Preferential Issue, subject to the receipt of necessary approvals.
Separately, the company informed that its board will meet on Monday, 17 May 2021, to consider and approve the audited financial results for the quarter and financial year ended 31 March 2021.
SPARC is engaged in research and experimental development on natural sciences and engineering. The company operates through pharmaceuticals research and development segment.
On a standalone basis, SPARC reported a net loss of Rs 67.62 crore in Q3 December 2020 as compared to a net loss of Rs 55.51 crore in Q3 December 2019. Net sales jumped 11.3% YoY to Rs 21.81 crore during the quarter.
Powered by Capital Market - Live News
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)
Dear Reader,
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.
Digital Editor
RECOMMENDED FOR YOU